HCA Healthcare, Inc. (HCA) Analyst Ratings & Price Targets

HCA Healthcare, Inc.

HCA · NYSE

Analyst Consensus

Buy

23 analysts

$410

Current

$475

Low

$463

Average

$485

High

Average target implies +12.90% versus the current price.

Analyst Ratings Synthesis

The supplied primary consensus is Buy across 23 analysts, with a mean price target of $462.50; its low and high are not provided. A separate Benzinga snapshot counts 27 analysts and reports a $499.13 consensus, ranging from $370 at KeyBanc to $635 at UBS, with UBS the most bullish and KeyBanc the least bullish in that dataset. Revisions over the recent evidence are predominantly downward: Oppenheimer cut $520 to $485, Morgan Stanley cut $425 to $380, and Barclays cut $427 to $402; Mizuho also cut $525 to $475 in an older action. The substantive disagreement is whether HCA's earnings growth can withstand current market pressures, supporting substantially higher targets, or warrants more conservative valuation assumptions.

Rating Actions

2 firms captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Oppenheimer Holdings	—	Outperform Retained Outperform rating; lowered price target	$485from $520	+18.4%	Jul 27, 2026	Open the report this row came from
Mizuho	—	Outperform Maintained Outperform rating; lowered price target	$475from $525	+16.0%	Oct 3, 2023	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BARCLAYS CAPITA

CANTOR FITZGERA

CITIGROUP

CO FORECST

DEUTSCHE BK SEC

GOLDMAN SACHS

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

LOOP CAPITAL MK

MIZUHO SECURITI

OPPENHEIMER HLD

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

STEPHENS INC

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: HCA
Type: Stock
Sector: Health Care
Industry: Services-General Medical & Surgical Hospitals, NEC
Exchange: NYSE

Nashville-based HCA Healthcare is one of the nation's leading providers of healthcare services comprising 189 hospitals and approximately 2,600 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 19 states and the United Kingdom. With its founding in 1968, HCA Healthcare created a new model for hospital care in the United States, using combined resources to strengthen hospitals, deliver patient-focused care and improve the practice of medicine. HCA Healthcare has conducted a number of clinical studies, including one that demonstrated that full-term delivery is healthier than early elective delivery of babies and another that identified a clinical protocol that can reduce bloodstream infections in ICU patients by 44%. HCA Healthcare is a learning health system that uses its approximately 47 million annual patient encounters to advance science, improve patient care and save lives.

Key Issues

Bullish view

Revenue rose from $70.6 billion to $75.6 billion and net income increased from $5.8 billion to $6.8 billion in fiscal 2025, supporting the case that operating growth can justify a premium valuation.

Bearish view

Morgan Stanley said it was reassessing HCA's growth prospects under current market conditions while cutting its target from $425 to $380, indicating that recent growth may not translate into sufficient forward upside.

Analyst Consensus

See all

Buy

23 analysts

$410

Current

$475

Low

$463

Average

$485

High

Average target implies +12.90% versus the current price.

Earnings History

BeatMissNo estimate

HCA Healthcare, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers